India, April 3 -- Genprex, Inc. (GNPX), a clinical-stage gene therapy company focused on cancer and diabetes, announced Wednesday the expansion of multiple clinical trial sites for its Acclaim-3 clinical study of Reqorsa Therapy in combination with Genentech's Tecentriq to treat extensive-stage small cell lung cancer or ES-SCLC.
In pre-market activity on the Nasdaq, Genprex shares were gaining around 7.7 percent to trade at $3.06.
Through its collaboration agreement with a large network of integrated, community-based oncology practices, the company said it has added multiple clinical trial sites for the trial.
ES-SCLC is an aggressive form of lung cancer that is presently incurable. ES-SCLC has a median progression free survival or PFS o...